Continuous glucose monitoring is one of healthtech's biggest markets β and one of its most uncomfortable products to wear. London-based Sava Technologies announced on October 9, 2026, per EU-Startups, that it has raised β¬32.08 million (about $36 million) in Series B funding to scale manufacturing and commercial readiness of its next-generation wearable biosensor. The round was led by Ascensia, with participation from Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments, and Pentland Ventures.
The company and its origins
Sava is a London healthtech founded in 2019 by Imperial College London bioengineers Renato Circi and RafaΓ«l Michali. The company's total funding now stands at β¬60.6 million (about $68 million) β a substantial capital base that reflects both the difficulty of hardware-plus-biology development and investor confidence in the platform's potential.
Sava's product is a wearable biosensor platform that detects molecules just beneath the skin. The key design goals: painless and continuous. The platform starts with glucose monitoring but is architected to track other biomarkers over time, making it a general-purpose sensing layer rather than a single-disease device.
The problem with legacy CGM technology
To understand why investors are betting on Sava, it helps to understand the incumbent technology. Today's continuous glucose monitors (CGMs) are dominated by a small number of players whose sensor technology is, by the standards of modern electronics, decades old. The sensors typically use needle-based filaments inserted under the skin, and while the category has transformed diabetes management, the devices remain bulky, sometimes painful, and visible β barriers to adoption for the much larger population of people with prediabetes or metabolic concerns who are not insulin-dependent.
Sava's co-founder and co-CEO Renato Circi has framed the opportunity directly around this stagnation: legacy continuous-monitoring technology has held the field back for decades. The thesis is that a genuinely painless, less intrusive sensor could expand the market far beyond current CGM users β from the roughly hundreds of millions of people with diabetes to the billions with metabolic health concerns.
The strategic investor angle
The round's lead investor deserves attention. Ascensia, a subsidiary of PHC Holdings Corporation (listed on the Tokyo Stock Exchange under ticker 6523), is not just writing a check β it has been appointed as Sava's commercialization and distribution partner, initially in Europe. This is the classic strategic-investor pattern in medtech: the startup gets capital plus a go-to-market partner with regulatory experience, distribution channels, and clinician relationships; the corporate investor gets a window into potentially disruptive technology and a path to deeper involvement.
For a hardware healthtech company, the manufacturing scale-up this round funds is one of the highest-risk phases of the journey. Medtech manufacturing requires quality systems, regulatory compliance, and yield management that software startups never face. Having a seasoned commercialization partner in place before scaling is a meaningful de-risking signal.
The biomarker platform thesis
Sava's long-term pitch extends beyond glucose. A wearable platform that can continuously detect molecules beneath the skin could, in principle, track lactate, ketones, cortisol, and other biomarkers β each opening a new clinical or wellness market. Platform plays command higher valuations than single-product companies because each new biomarker multiplies the addressable market without requiring a new device. The risk is that multi-analyte sensing is scientifically hard, and investors are underwriting the glucose product first, the platform second.
Why it matters for founders
Sava's trajectory offers several lessons for healthtech founders. First, strategic investors can be worth more than their capital β Ascensia's distribution partnership may matter more than the β¬32 million. Second, framing your company against stagnant incumbents ("legacy technology has held the field back for decades") is a powerful narrative when the incumbents' products are visibly uncomfortable. Third, medtech timelines are long β seven years from founding to commercial readiness β so founders need investors with the patience and pockets for hardware. The β¬60.6 million total raised reflects the real cost of building regulated hardware.
Why it matters for investors
The CGM market is large and growing, driven by diabetes prevalence and the expanding "metabolic health" consumer segment. Sava's bet is that painlessness unlocks the next order of magnitude of users. Key diligence questions: clinical accuracy versus incumbents, manufacturing yield at scale, regulatory pathway timing in Europe and beyond, and whether the multi-biomarker platform is real or aspirational. The Ascensia partnership answers the distribution question in Europe; the manufacturing question is what this round is designed to answer.
Angeled.com connects founders with investors.
Read Next
General Translation Raises $27 Million Series A Led by a16z to Build Agent-First Localization Infrastructure
LangChain Raises $300 Million Led by CapitalG at a $3 Billion Valuation to Build the Agent Stack
Mount Thor Raises $45 Million to Run Cloud Fleets of Macs for AI Agents
OpenAI Reportedly Raises $15 Billion at a $1.25 Trillion Valuation
Q-CTRL Raises $290 Million Series C Led by Salesforce Ventures, Reaching Unicorn Status
SE3 Raises $30 Million Series A Led by Accel



